全文获取类型
收费全文 | 2050篇 |
免费 | 283篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 79篇 |
妇产科学 | 26篇 |
基础医学 | 151篇 |
口腔科学 | 74篇 |
临床医学 | 287篇 |
内科学 | 518篇 |
皮肤病学 | 53篇 |
神经病学 | 90篇 |
特种医学 | 306篇 |
外科学 | 158篇 |
综合类 | 19篇 |
预防医学 | 365篇 |
眼科学 | 24篇 |
药学 | 58篇 |
中国医学 | 2篇 |
肿瘤学 | 134篇 |
出版年
2023年 | 50篇 |
2022年 | 17篇 |
2021年 | 18篇 |
2020年 | 45篇 |
2019年 | 23篇 |
2018年 | 66篇 |
2017年 | 41篇 |
2016年 | 57篇 |
2015年 | 65篇 |
2014年 | 105篇 |
2013年 | 146篇 |
2012年 | 65篇 |
2011年 | 81篇 |
2010年 | 81篇 |
2009年 | 95篇 |
2008年 | 75篇 |
2007年 | 92篇 |
2006年 | 73篇 |
2005年 | 64篇 |
2004年 | 55篇 |
2003年 | 25篇 |
2002年 | 32篇 |
2001年 | 31篇 |
2000年 | 36篇 |
1999年 | 44篇 |
1998年 | 69篇 |
1997年 | 92篇 |
1996年 | 85篇 |
1995年 | 62篇 |
1994年 | 65篇 |
1993年 | 55篇 |
1992年 | 23篇 |
1991年 | 18篇 |
1990年 | 34篇 |
1989年 | 52篇 |
1988年 | 40篇 |
1987年 | 44篇 |
1986年 | 35篇 |
1985年 | 35篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 24篇 |
1981年 | 31篇 |
1980年 | 18篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 10篇 |
1967年 | 2篇 |
排序方式: 共有2355条查询结果,搜索用时 0 毫秒
51.
Deirdre Desmond Natasha Layton Jacob Bentley Fleur Heleen Boot Johan Borg Bishnu Maya Dhungana 《Disability and rehabilitation. Assistive technology》2018,13(5):437-444
AbstractAssistive technology (AT) is a powerful enabler of participation. The World Health Organization’s Global Collaboration on Assistive Technology (GATE) programme is actively working towards access to assistive technology for all. Developed through collaborative work as a part of the Global Research, Innovation and Education on Assistive Technology (GREAT) Summit, this position paper provides a “state of the science” view of AT users, conceptualized as “People” within the set of GATE strategic “P”s. People are at the core of policy, products, personnel and provision. AT is an interface between the person and the life they would like to lead. People’s preferences, perspectives and goals are fundamental to defining and determining the success of AT. Maximizing the impact of AT in enabling participation requires an individualized and holistic understanding of the value and meaning of AT for the individual, taking a universal model perspective, focusing on the person, in context, and then considering the condition and/or the technology. This paper aims to situate and emphasize people at the centre of AT systems: we highlight personal meanings and perspectives on AT use and consider the role of advocacy, empowerment and co-design in developing and driving AT processes. 相似文献
52.
53.
54.
55.
56.
57.
58.
59.
JD Roberts JC Herkert J Rutberg SM Nikkel ACP Wiesfeld D Dooijes RM Gow JP van Tintelen MH Gollob 《Clinical genetics》2013,83(5):452-456
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease that predominantly affects the right ventricle and is associated with ventricular arrhythmias that may lead to sudden cardiac death. Mutations within at least seven separate genes have been identified to cause ARVC, however a genetic culprit remains elusive in approximately 50% of cases. Although negative genetic testing may be secondary to pathogenic mutations within undiscovered genes, an alternative explanation may be the presence of large deletions or duplications involving known genes. These large copy number variants may not be detected with standard clinical genetic testing which is presently limited to direct DNA sequencing. We describe two cases of ARVC possessing large deletions involving plakophilin‐2 (PKP2) identified with microarray analysis and/or multiplex ligation‐dependent probe amplification (MLPA) that would have been classified as genotype negative with standard clinical genetic testing. A deletion of the entire coding region of PKP2 excluding exon 1 was identified in patient 1 and his son. In patient 2, MLPA analysis of PKP2 revealed deletion of the entire gene with subsequent microarray analysis demonstrating a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1. These findings support screening for large copy number variants in clinically suspected ARVC cases without clear disease causing mutations following initial sequencing analysis. 相似文献
60.
Stephanie R McKeown Paul Hatfield Robin JD Prestwich Richard E Shaffer Roger E Taylor 《The British journal of radiology》2015,88(1056)
Most radiotherapy (RT) involves the use of high doses (>50 Gy) to treat malignant disease. However, low to intermediate doses (approximately 3–50 Gy) can provide effective control of a number of benign conditions, ranging from inflammatory/proliferative disorders (e.g. Dupuytren''s disease, heterotopic ossification, keloid scarring, pigmented villonodular synovitis) to benign tumours (e.g. glomus tumours or juvenile nasopharyngeal angiofibromas). Current use in UK RT departments is very variable. This review identifies those benign diseases for which RT provides good control of symptoms with, for the most part, minimal side effects. However, exposure to radiation has the potential to cause a radiation-induced cancer (RIC) many years after treatment. The evidence for the magnitude of this risk comes from many disparate sources and is constrained by the small number of long-term studies in relevant clinical cohorts. This review considers the types of evidence available, i.e. theoretical models, phantom studies, epidemiological studies, long-term follow-up of cancer patients and those treated for benign disease, although many of the latter data pertain to treatments that are no longer used. Informative studies are summarized and considered in relation to the potential for development of a RIC in a range of key tissues (skin, brain etc.). Overall, the evidence suggests that the risks of cancer following RT for benign disease for currently advised protocols are small, especially in older patients. However, the balance of risk vs benefit needs to be considered in younger adults and especially if RT is being considered in adolescents or children. 相似文献